Oxford BioMedica PLC OXB

Morningstar Rating
GBX522.00 +9.00 (1.75%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

OXB is trading at a LOCK|#?HqG> premium.
Price
£5.13
Fair Value
LOCK|&RPSTL
Uncertainty
LOCK|rJ F$f>
1-Star Price
LOCK|RdYf$Q
5-Star Price
LOCK|@J^<trf
Economic Moat
LOCK|Mc
Capital Allocation
—

Trading Information

Previous Close Price
GBX513.00
Day Range
GBX513.00–531.00
52-Week Range
GBX420.00–962.00
Bid/Ask
GBX520.00 / GBX525.00
Shares Outstanding
121.05M
Market Cap
GBX63.19B
Volume/Avg
55,101 / 751,646

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
3.50
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
986

Valuation

Metric
OXB
Price/Earnings (Normalized)
—
Price/Book Value
10.69
Price/Sales
3.50
Price/Cash Flow
—
Price/Earnings
OXB

Financial Strength

Metric
OXB
Quick Ratio
1.76
Current Ratio
2.21
Interest Coverage
−2.05
Quick Ratio
OXB

Profitability

Metric
OXB
Return on Assets (Normalized)
−13.55%
Return on Equity (Normalized)
−62.55%
Return on Invested Capital (Normalized)
−14.37%
Return on Assets
OXB

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|dFClbFLOCK|%!DZq$128B
Moderna Inc
MRNA
LOCK|^qYcpL%LOCK|sp$79B
Regeneron Pharmaceuticals Inc
REGN
LOCK|?kRnrCQLOCK|vVp#$76B
argenx SE ADR
ARGX
LOCK|D!w<W<LOCK|<w$50B
BeOne Medicines Ltd ADR
ONC
LOCK|>bFNb^LOCK|Mxz$41B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|p?pNlqLOCK|?$Jx$30B
Royalty Pharma PLC Class A
RPRX
LOCK|VF<^&&z%LOCK|cg^&l$25B
BioNTech SE ADR
BNTX
LOCK|QK%@##LOCK|QF$23B
Incyte Corp
INCY
LOCK|!P?r^?LOCK|$^$23B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|W$?!dc#LOCK|^B#$14B

Sponsor Center